Gut Microbiota Market Report 2026

Gut Microbiota Market Overview

• Gut Microbiota market size has reached to $0.65 billion in 2025 • Expected to grow to $1.47 billion in 2030 at a compound annual growth rate (CAGR) of 17.7% • Growth Driver: Growing Demand For Personalized Medicine Fueling The Growth Of The Market Due To Rising Focus On Tailored Healthcare Solutions • Market Trend: Advancements In Microbiota Profiling For Early Disease Detection And Personalized Treatments • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Gut Microbiota Market?

Gut microbiota refers to the complex community of microorganisms, including bacteria, viruses, fungi, and other microbes, that reside in the gastrointestinal tract. These microbes play a vital role in digestion, immune function, and overall health by influencing metabolism and protecting against harmful pathogens. The main product types in the gut microbiota market are prebiotics, probiotics, drugs, supplements, and other products. Prebiotics refer to non-digestible food components, primarily dietary fibers, that serve as nourishment for beneficial bacteria in the gut. These products are distributed through several channels, such as pharmacies and drugstores, online retail, health food stores, supermarkets and hypermarkets, and specialty stores, for various applications, such as digestive health, immune health, weight management, mental health, and cardiovascular health, and they cater to different end-users, including adults, children, and the elderly.

What Is The Gut Microbiota Market Growth Forecast?

The gut microbiota market size is expected to see rapid growth in the next few years. It will grow to $1.47 billion in 2030 at a compound annual growth rate (CAGR) of 17.7%. The growth in the forecast period can be attributed to increasing development of microbiome-targeted therapeutics, rising investments in gut health research, expansion of personalized nutrition platforms, growing integration of microbiome diagnostics, increasing focus on preventive healthcare solutions. Major trends in the forecast period include increasing adoption of probiotic and prebiotic products, rising focus on personalized nutrition solutions, growing research in microbiome-based therapies, expansion of functional and fermented food consumption, enhanced use of gut health diagnostic tools.

What Is The Driver Of The Gut Microbiota Market?

The growing demand for personalized medicine is expected to propel the growth of the gut microbiota market going forward. Personalized medicine involves tailoring treatments to individual patients based on their genetic, environmental, and lifestyle factors to optimize outcomes and improve care. The demand for personalized medicine is growing as advancements in genomics and biotechnology enable more precise identification of genetic profiles, allowing for tailored treatments that improve effectiveness and reduce side effects. Personalized medicine is useful for gut microbiota by tailoring treatments based on an individual's unique microbiome composition, optimizing gut health, and improving outcomes for digestive and metabolic disorders. For instance, in February 2024, according to the Personalized Medicine Coalition (PMC), a US-based nonprofit organization, the U.S. Food and Drug Administration (FDA) approved 26 new personalized medicines in 2023, marking a significant rise compared to the 12 approved in 2022. Therefore, the growing demand for personalized medicine is driving the growth of the gut microbiota industry.

Key Players In The Global Gut Microbiota Market

Major companies operating in the gut microbiota market are Danone S.A., DuPont de Nemours Inc., International Flavors & Fragrances Inc., Seres Therapeutics, Yakult Honsha Co. Ltd., Chr. Hansen Holding A/S, Lallemand Inc., Lifeway Foods Inc., BioGaia AB, Probi AB, Seed Health, Enterome, Vedanta Biosciences Inc., Evolve BioSystems Inc., Winclove Probiotics B.V., Kallyope Inc., Sun Genomics Inc., Synlogic Inc., OpenBiome, Codex Labs Corp.

Global Gut Microbiota Market Trends and Insights

Major companies operating in the gut microbiota market are focusing on developing innovative solutions, such as orally administered fecal microbiota, to address various gastrointestinal diseases and disorders. Orally administered fecal microbiota refers to a treatment in which a capsule or pill containing beneficial bacteria from a healthy donor's stool is taken to restore balance to the gut microbiome. For instance, in April 2023, Seres Therapeutics Inc., a US-based microbiome therapeutics platform company, received FDA approval for Vowst, the first oral fecal microbiota product designed to prevent recurrent Clostridioides difficile (C. difficile) infection (CDI) in individuals aged 18 and older. Vowst is intended for use after antibacterial treatment for recurrent CDI. This approval marks a significant advancement in CDI treatment, providing a more accessible and patient-friendly alternative to traditional fecal microbiota transplants, which are typically administered via colonoscopy or enema. Its oral formulation may improve treatment adherence and expand the adoption of microbiome-based therapies in healthcare.

What Are Latest Mergers And Acquisitions In The Gut Microbiota Market?

In April 2023, Archer-Daniels-Midland Company (ADM), a US-based food processing company, partnered with Brightseed to develop scientifically backed synbiotic products that support gut microbiome health. This collaboration leverages Brightseed’s AI-driven molecular insights to create evidence-based formulations aimed at enhancing immune function, metabolic health, and mental well-being. By combining ADM’s expertise in nutrition with Brightseed’s AI technology, the partnership seeks to advance gut health solutions rooted in cutting-edge science. Brightseed is a US-based biotechnology company specializing in gut microbiome research through its proprietary AI platform.

What Defines the Gut Microbiota Market?

The gut microbiota market consists of sales of postbiotics, personalized nutrition products, and fecal microbiota transplantation (FMT) preparations. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Gut Microbiota Market Report 2026?

The gut microbiota market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the gut microbiota industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.